초록 ▼

A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutical

A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity.

대표청구항 ▼

1. A method of preventing or treating a proliferative disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family wherein the ribonuclease T2 binds actin in either its active or non-active ribonucleol

1. A method of preventing or treating a proliferative disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family wherein the ribonuclease T2 binds actin in either its active or non-active ribonucleolytic form. 2. The method of claim 1, wherein said proliferative disorder is selected from the group consisting of arthritis, rheumatoid arthritis, diabetic retinopathy, restenosis, proliferative vitreoretinopathy, chronic inflammatory proliferative disease, dermatofibroma and psoriasis. 3. The method of claim 2, wherein said restenosis is in-stent restenosis or vascular graft restenosis. 4. A method of preventing or treating an inflammatory disease or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family wherein the ribonuclease T2 binds actin in either its active or non-active ribonucleolytic form. 5. The method of claim 4, wherein said inflammatory disease or condition is selected from the group consisting of meningitis, cerebral edema, arthritis, nephritis, adult respiratory distress syndrome, pancreatitis, myositis, neuritis, connective tissue diseases, phlebitis, arteritis, vasculitis, allergy, anaphylaxis, ehrlichiosis, gout, organ transplants and/or ulcerative colitis. 6. A method of preventing or treating an ischemic disease or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family wherein the ribonuclease T2 binds actin in either its active or non-active ribonucleolytic form. 7. The method of claim 6, wherein said ischemic disease or condition is selected from the group consisting of myocardial ischemia or cerebral ischemia. 8. The method of any one of claim 1, 4 or 6, wherein said ribonuclease of the T2 family comprises a T2 ribonuclease protein having a molecular weight of between 24-36 kDa. 9. The method of any one of claim 1, 4 or 6, wherein said ribonuclease of the T2 family is devoid of ribonuclease activity. 10. The method of any one of claim 1, 4 or 6, wherein an actin binding activity of said ribonuclease protein is boiling stable. 11. The method of any one of claim 1, 4 or 6, wherein administering to the subject said therapeutically effective amount of said ribonuclease of the T2 family is effected by parenteral administration. 12. The method of any one of claim 1, 4 or 6, wherein administering is by an administration mode selected from the group consisting of oral administration, topical administration, transmucosal administration, parenteral administration, rectal administration and by inhalation. 13. The method of any one of claim 1, 4 or 6, wherein said ribonuclease of the T2 family is A. niger B1 RNase. 14. The method of any one of claim 1, 4 or 6, wherein said ribonuclease of the T2 family is selected from the group consisting of RNase T2, RNase Rh, RNase M, RNase Trv, RNase Irp, RNase Le2, RNase Phyb, RNase LE, RNase MC, RNase CL1, RNase Bsp1, RNase RCL2, RNase Dm, RNase Oy and RNase Tp, RNase HI0526, RNase I, Rnase Irp1, RNS2, RNase 3, RNase 1, RNase LX and RNase 6PL. 15. The method of any one of claim 1, 4 or 6, wherein said ribonuclease is a T2 ribonuclease from an organism selected from the group consisting of Aeromonas hydrophila, Haemophilus influenzae, Escherichia coli, Aspergillus oryzae, Aspergillus phoenicis, Rhisopus niveus, Trichoderma viride, Lentinula edodes, Irpex lacteus, Physarum polycephlum, Arabidopsis thaliana, Lycopersicon esculentum, Nicotiana alata, Malus domestica, Pyrus pyrifolia, Momordica charantia, Gallus gallus, Rana catesbeiana, Drosophila melanogaster, Crassostera gigus, Todarodes pasificus and Homo sapiens.